Rani Therapeutics Holdings, Inc (RANI) insider trading

Every open-market stock purchase and sale by Rani Therapeutics Holdings, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Talat Imran (CEO) and 1 other bought $50K in the last 90 days, growing their stake 8%.
  • Alireza Javadi (CTO) sold $301 in the last 90 days.

Last 12 months: insiders bought $50K (3 buys) and sold $15.7M (2 sales). Last close $0.78 on Aug 6, 2026.

Recent RANI insider trades

DateInsiderTradeValue
Aug 3, 2026Michelle Gilson (Insider)Bought (not open market)—
Jul 21, 2026Mir A Imran (Insider)Bought$24.8K
Jul 17, 2026Talat Imran (CEO)Bought$25.2K
Jul 17, 2026Nicholas Maestas (CFO)Bought (not open market)—
Jun 27, 2026Talat Imran (CEO)Sold (not open market)$5.9K
Jun 27, 2026Alireza Javadi (CTO)Sold (not open market)$229
Jun 3, 2026Talat Imran (CEO)Bought (not open market)—
Jun 3, 2026Alireza Javadi (CTO)Bought (not open market)—
Jun 3, 2026Kate McKinley (C-suite exec)Bought (not open market)—
May 28, 2026Vasudev Jaiprakash Bailey (Insider)Bought (not open market)—
May 28, 2026Dennis A Ausiello (Insider)Bought (not open market)—
May 28, 2026Lisa Ann Rometty (Insider)Bought (not open market)—
May 28, 2026Mir A Imran (Insider)Bought (not open market)—
May 28, 2026Jean Luc Butel (Insider)Bought (not open market)—
May 28, 2026Abraham Bassan (Insider)Bought (not open market)—
Mar 27, 2026Talat Imran (CEO)Sold (not open market)$7.4K
Mar 27, 2026Alireza Javadi (CTO)Sold$301
Mar 22, 2026Talat Imran (CEO)Sold (not open market)$10.1K
Dec 27, 2025Talat Imran (CEO)Sold (not open market)$11.1K
Oct 23, 2025Mir A Imran (Insider)Bought—
Oct 23, 2025Vasudev Jaiprakash Bailey (Insider)Bought (not open market)—
Oct 23, 2025Abraham Bassan (Insider)Bought (not open market)—
Oct 21, 2025South Cone Investments Limited Partnership (10% owner)Sold$11.1M
Oct 20, 2025South Cone Investments Limited Partnership (10% owner)Sold$4.6M

Who's trading RANI

Get free alerts when an insider at Rani Therapeutics Holdings, Inc files a new trade →